Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief Report
Discontinuing ICB after 24 months did not negatively impact OS in our real-world cohort. Although limited by the small sample size, these findings support the potential of gut microbiota profiling as a promising tool to guide ICB duration. Integrating a translational multiomic algorithm, in particular microbial signals, may help personalize treatment strategies and safely shorten immunotherapy courses.
Authors
- Claudia Parisi (ORCID: https://orcid.org/0000-0002-6259-8234)
- Francesco Facchinetti (ORCID: https://orcid.org/0000-0001-6313-6341)
- Priscilla Cascetta (ORCID: https://orcid.org/0000-0002-4252-7543)
- Benjamin Besse (ORCID: https://orcid.org/0000-0001-5090-8189)
- David Planchard (ORCID: https://orcid.org/0000-0002-1565-8310)
- Adele Bonato
- Anna Reni (ORCID: https://orcid.org/0009-0006-3586-0694)
- May‐Lucie Meyer (ORCID: https://orcid.org/0000-0003-2091-9578)
- Lisa Derosa (ORCID: https://orcid.org/0000-0003-0527-2964)
- Mariona Riudavets (ORCID: https://orcid.org/0000-0002-5202-0631)
- Jordi Remón (ORCID: https://orcid.org/0000-0002-9462-875X)
- Lorenzo Belluomini (ORCID: https://orcid.org/0000-0003-1981-5499)
- Fabrice Barlési (ORCID: https://orcid.org/0000-0001-5793-3539)
Institutions
- University of Verona (IT)
- Inserm (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Humanitas Gavazzeni (IT)
- Azienda Ospedaliera Sant'Andrea (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Sapienza University of Rome (IT)
- University of Lausanne (CH)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-10-30
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100928
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00